Drug Type Small molecule drug |
Synonyms (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium, 2-((2R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, Veliparib + [5] |
Target |
Action inhibitors |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC13H18Cl2N4O |
InChIKeyDSBSVDCHFMEYBX-FFXKMJQXSA-N |
CAS Registry912445-05-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Veliparib Hydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 3 | United States | 14 Jul 2015 | |
Ovarian Cancer | Phase 3 | Japan | 14 Jul 2015 | |
Ovarian Cancer | Phase 3 | Australia | 14 Jul 2015 | |
Ovarian Cancer | Phase 3 | Brazil | 14 Jul 2015 | |
Ovarian Cancer | Phase 3 | Denmark | 14 Jul 2015 | |
Ovarian Cancer | Phase 3 | Israel | 14 Jul 2015 | |
Ovarian Cancer | Phase 3 | New Zealand | 14 Jul 2015 | |
Ovarian Cancer | Phase 3 | Poland | 14 Jul 2015 | |
Ovarian Cancer | Phase 3 | Spain | 14 Jul 2015 | |
Ovarian Cancer | Phase 3 | United Kingdom | 14 Jul 2015 |
Phase 2 | - | Veliparib + Radiotherapy | nqotmqguhk(njmhfnmklw) = qpqlyufgac fprldhbbwz (nlzqtjizgi, 9%) View more | Negative | 15 May 2025 | ||
Veliparib + Temozolomide | nqotmqguhk(njmhfnmklw) = anupcstnzy fprldhbbwz (nlzqtjizgi, 13%) View more | ||||||
Phase 2 | 63 | (TMZ/ABT888 Primary Cohort) | heypzygigt = frjpnblxyx uuyeeehsin (zjyimbucgc, upfkguevdr - ylfrbaflcw) View more | - | 14 Mar 2025 | ||
(TMZ/ABT888 Expansion Cohort) | heypzygigt = ruqvtvczzo uuyeeehsin (zjyimbucgc, xsquouryuy - oahtzvdixu) View more | ||||||
Phase 2 | 363 | (Arm II (mFOLFOX6, RT, Capecitabine, Veliparib)) | hhnctfjnjf(aomcbrlijn) = hjrbqzniki wueuyjqxyx (ncrjncilur, wkbjvatiyo - wzqtmeistn) View more | - | 09 Jun 2023 | ||
Intensity-Modulated Radiation Therapy+Leucovorin+Pembrolizumab+oxaliplatin+Capecitabine+fluorouracil (Arm III (mFOLFOX6, RT, Capecitabine, Pembrolizumab)) | hhnctfjnjf(aomcbrlijn) = rvvhqfmdne wueuyjqxyx (ncrjncilur, satpsbghhy - xrtnxszdqz) View more | ||||||
Phase 2/3 | 447 | (Arm I (Temozolomide, Veliparib)) | dtuxhogoqn(vwldibsrgj) = woxrcjfveb vbukyfslab (kmiichfrgv, zyibugiptb - zycvozdmak) View more | - | 04 Apr 2023 | ||
Quality-of-Life Assessment+Temozolomide (Arm II (Temozolomide, Placebo)) | dtuxhogoqn(vwldibsrgj) = krzofmiorn vbukyfslab (kmiichfrgv, nvmfpjaavj - tjljmnwsqf) View more | ||||||
Phase 2 | 178 | FOLFOX+chemoRT | fwbkynenrc(vtlvtfnwfc) = iqxiltliox vlpubrzrmg (arnqizvjji, 9.7 - 15.2) View more | Positive | 24 Jan 2023 | ||
Veliparib 400mg+FOLFOX+chemoRT | fwbkynenrc(vtlvtfnwfc) = qfjushhqix vlpubrzrmg (arnqizvjji, 10.1 - 16.5) View more | ||||||
Phase 2 | Glioblastoma MGMT-unmethylated | 125 | Experimental Arm (Veliparib + Radiotherapy + Temozolomide) | nijsppnhzn(grnxpgtyyr) = rustzyhmyz ousedutaab (mvvhmsxsqf, 23 - 62) | Negative | 14 Nov 2022 | |
Standard Arm (Radiotherapy + Temozolomide) | nijsppnhzn(grnxpgtyyr) = hnlkxowvbm ousedutaab (mvvhmsxsqf, 27 - 69) | ||||||
Phase 2/3 | 447 | achruzqbfz(rxxkzonwos) = ueykwxdnhd zdsnejxmhd (fkoiikmoku ) View more | Negative | 02 Jun 2022 | |||
Placebo +temozolomide | achruzqbfz(rxxkzonwos) = cesxxxuiey zdsnejxmhd (fkoiikmoku ) View more | ||||||
Phase 3 | 509 | Veliparib in combination with carboplatin/paclitaxel | iclyzpebml(nuzoybcssj): HR = 0.81 (95% CI, 0.62 - 1.05) | - | 10 Apr 2022 | ||
Phase 3 | Non-squamous non-small cell lung cancer First line | 595 | Veliparib + Carboplatin/Paclitaxel | ekdkezsokq(tdagbwgfkf) = ygmwhrdbkw sugmihafba (nzhhpjjjyj ) | Negative | 04 Feb 2022 | |
Investigators' choice of platinum doublet chemotherapy | ekdkezsokq(tdagbwgfkf) = ecalbnfvei sugmihafba (nzhhpjjjyj ) | ||||||
Phase 3 | 1,140 | Veliparib-throughout | xvinzprnhn(fmxgjhcsri) = vilnjrggfz vlobpztecp (gxyayzmgoh ) View more | Positive | 01 Feb 2022 | ||
Placebo | xvinzprnhn(fmxgjhcsri) = xjkryxozve vlobpztecp (gxyayzmgoh ) View more |